• Je něco špatně v tomto záznamu ?

Influence of skin permeation enhancers on the transdermal delivery of palonosetron: An in vitro evaluation

Anroop B. Nair, Shery Jacob, Bandar E. Al-Dhubiab, Rakan Naser Alhumam

. 2018 ; 16 (3) : 192-197.

Jazyk angličtina Země Česko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18039972

It is proposed that the low skin permeation potential of palonosetron could be enhanced by the inclusion of chemical permeation enhancers. The objective of this study is to evaluate the influence of various chemical enhancers on the transdermal permeation of palonosetron. Different drugs in adhesive transdermal patches (F1–F5) were prepared using five pressure sensitive adhesives; Duro-Tak 87-4098, Duro-Tak 87-2074, Duro-Tak 87-900A, Duro-Tak 87-9301 and Duro-Tak 87-2287. Patches prepared using Duro-Tak 87-9301 (F5) was further combined with four well-known chemical enhancers. The influence of permeation enhancers (propylene glycol, diethylene glycol monoethyl ether, Tween 80 and oleic acid) on the transdermal flux was evaluated ex vivo. Release of the drug from fabricated patches was carried out for a period of 6 h. Greater amount of drug (12% w/w) was incorporated in the patches prepared using Duro-Tak 87-9301 (F5). Incorporation of skin permeation enhancers significantly (P < 0.001) improves the transdermal flux of palonosetron. Among the permeation enhancers, propylene glycol (5% w/w) shows highest permeation (53.12 ± 5.62 μg/cm2/h), which is ∼4 folds higher than control. Biphasic drug release was noticed in the prepared patches and the rate of release was relatively high with patch F7. This study reveals that the optimized transdermal system with propylene glycol as permeation enhancers can provide effective therapeutic level of palonosetron.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc18039972
003      
CZ-PrNML
005      
20190304144050.0
007      
ta
008      
181211s2018 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jab.2017.12.003 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Nair, Anroop B. $u King Faisal University, College of Clinical Pharmacy, Department of Pharmaceutical Sciences, Al-Ahsa, Saudi Arabia
245    10
$a Influence of skin permeation enhancers on the transdermal delivery of palonosetron: An in vitro evaluation / $c Anroop B. Nair, Shery Jacob, Bandar E. Al-Dhubiab, Rakan Naser Alhumam
504    __
$a Literatura
520    9_
$a It is proposed that the low skin permeation potential of palonosetron could be enhanced by the inclusion of chemical permeation enhancers. The objective of this study is to evaluate the influence of various chemical enhancers on the transdermal permeation of palonosetron. Different drugs in adhesive transdermal patches (F1–F5) were prepared using five pressure sensitive adhesives; Duro-Tak 87-4098, Duro-Tak 87-2074, Duro-Tak 87-900A, Duro-Tak 87-9301 and Duro-Tak 87-2287. Patches prepared using Duro-Tak 87-9301 (F5) was further combined with four well-known chemical enhancers. The influence of permeation enhancers (propylene glycol, diethylene glycol monoethyl ether, Tween 80 and oleic acid) on the transdermal flux was evaluated ex vivo. Release of the drug from fabricated patches was carried out for a period of 6 h. Greater amount of drug (12% w/w) was incorporated in the patches prepared using Duro-Tak 87-9301 (F5). Incorporation of skin permeation enhancers significantly (P < 0.001) improves the transdermal flux of palonosetron. Among the permeation enhancers, propylene glycol (5% w/w) shows highest permeation (53.12 ± 5.62 μg/cm2/h), which is ∼4 folds higher than control. Biphasic drug release was noticed in the prepared patches and the rate of release was relatively high with patch F7. This study reveals that the optimized transdermal system with propylene glycol as permeation enhancers can provide effective therapeutic level of palonosetron.
650    _2
$a techniky in vitro $7 D066298
650    12
$a palonosetron $x aplikace a dávkování $x farmakokinetika $7 D000077924
650    _2
$a transdermální náplast $7 D057968
650    12
$a adjuvancia farmaceutická $x klasifikace $7 D000277
650    _2
$a propylenglykol $7 D019946
650    12
$a kožní absorpce $7 D012869
650    _2
$a antitumorózní látky $x škodlivé účinky $7 D000970
650    _2
$a nauzea $x farmakoterapie $x chemicky indukované $7 D009325
650    _2
$a zvracení $x farmakoterapie $x chemicky indukované $7 D014839
650    _2
$a zvířata $7 D000818
650    _2
$a potkani Wistar $7 D017208
650    _2
$a uvolňování léčiv $7 D065546
653    00
$a enhancery
653    00
$a urychlovače permeace
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jacob, Shery $u Gulf Medical University, College of Pharmacy, Department of Pharmaceutical Sciences, Ajman, United Arab Emirates
700    1_
$a Al-Dhubiab, Bandar E. $u King Faisal University, College of Clinical Pharmacy, Department of Pharmaceutical Sciences, Al-Ahsa, Saudi Arabia
700    1_
$a Alhumam, Rakan Naser $u King Faisal University, College of Clinical Pharmacy, Department of Pharmaceutical Sciences, Al-Ahsa, Saudi Arabia
773    0_
$t Journal of applied biomedicine $x 1214-021X $g Roč. 16, č. 3 (2018), s. 192-197 $w MED00012667
856    41
$u https://jab.zsf.jcu.cz/pdfs/jab/2018/03/06.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2301 $c 1249 $y 4 $z 0
990    __
$a 20181211090250 $b ABA008
991    __
$a 20190304144402 $b ABA008
999    __
$a ok $b bmc $g 1358046 $s 1037035
BAS    __
$a 3
BMC    __
$a 2018 $b 16 $c 3 $d 192-197 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
LZP    __
$c NLK185 $d 20190304 $a NLK 2018-52/dk

Najít záznam

Citační ukazatele

Možnosti archivace